A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal ...

The first-in-human SCS trial saw all three SMA patients able to increase their walking distance within six minutes to 20 meters.

Media: As Trump enters the White House ... Essays on Love: Shane Burcaw, who has spinal muscular atrophy, and his nondisabled wife examine “interabled” relationships in a new essay collection.

Tennis: See the latest upsets and updates from the Australian Open ... The romance of caregiving: Shane Burcaw, who has spinal muscular atrophy, and his wife, who is not disabled, examine ...

Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.

Seeking urgent Union government intervention to overcome the lack of affordable access to medicines for treating Spinal Muscular Atrophy (SMA) and the need to allow local manufacturers to make ...

January 08, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...